Core Insights - CervoMed Inc. announced significant findings from the AscenD-LB Phase 2a trial, indicating that plasma GFAP levels correlate with dementia severity in patients with dementia with Lewy bodies (DLB) and that neflamapimod treatment significantly reduces plasma GFAP levels compared to placebo [1][2][3] Group 1: Trial Results - The AscenD-LB Phase 2a trial demonstrated that neflamapimod treatment led to a significant reduction in plasma GFAP levels in DLB patients, which was associated with improvements in clinical outcomes measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB) [1][2] - In early-stage DLB patients, the placebo group experienced a mean increase of 14.1 pg/mL in plasma GFAP, while the neflamapimod group saw a mean reduction of 10.6 pg/mL, with a statistically significant difference (p=0.04) [3] - In advanced DLB patients, the neflamapimod treatment resulted in a mean reduction of 14.0 pg/mL in plasma GFAP, although the difference compared to placebo was not statistically significant [3] Group 2: Biomarker Significance - Plasma GFAP has been validated as a biomarker for evaluating therapeutic effects on DLB-specific disease processes, with baseline GFAP levels correlating with dementia severity [2][4] - Recent studies indicate that plasma GFAP is elevated in prodromal DLB patients compared to healthy controls, suggesting its potential as a marker for early disease processes [4][5] Group 3: Ongoing Studies - The RewinD-LB Phase 2b study is currently underway, evaluating the efficacy of neflamapimod in up to 160 patients with very mild or mild DLB, with topline data expected in December 2024 [6] - The study is funded by a $21 million grant from the National Institutes of Health's National Institute on Aging and aims to assess changes in CDR-SB as the primary endpoint [6]

BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will present virtually at the Emerging Growth Conference. CervoMed Inc. (the "Company") is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain pene ...

Agenda Topics: Right Disease, Right Drug, Right Patient, Right Trial Overview of the DLB disease state, unmet need and current treatment landscape for patients Understanding the role of the basal forebrain cholinergic system in clinical disease expression and progression in patients with DLB Neflamapimod mechanism of action and therapeutic potential to reverse disease progression in the basal forebrain cholinergic system Understanding the role of plasma phosphorylated tau in the selection of patients for in ...

The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rank ...

CervoMed's ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in up to 160 patients with very mild or mild dementia due to DLB. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. Patients with Alzheimer's Disease-related co-pathology, assessed by a blood biomarker (plasma ptau181), wi ...

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 30, 2024 Registration No. 333-279343 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ CERVOMED INC. (Exact name of registrant as specified in its charter) ____________________ (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 30-0645032 (Primary Standard Industrial Classifica ...

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will cont ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CRVO NASDAQ Capital Market May 15, 2024 Date of Report (Date of earliest event reported) 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (Address of principal executive offices) (Zip Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Pre-commencement communications p ...

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024. "Building on a year of high operational and clinical achievement, already in 2024, we have strengthened our financial resources and published data that further positions our lead clinical program, neflamapimod, as a highly differentiated, potential first-to-market ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CervoMed Inc. Condensed Consolidated Statements of Operations (unaudited) The fair value of the 2020 Notes and the 2021 Notes, and collectively the Convertible Notes (Note 7) as of March 31, 2023 were estimated as the combination of a zero-coupon bond and a call option. The combined values for each of the 2020 Notes and the 2021 Notes as of March 31, 2023 were then weighted by the probability of completing a financing ...